Acquisition by Karbe Frank of 25000 shares of Phathom Pharmaceuticals at 10.1645 subject to Rule 16b-3
PHAT Stock | USD 8.93 0.36 3.88% |
Slightly above 67% of Phathom Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Phathom Pharmaceuticals stock suggests that many investors are alarmed at this time. Phathom Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Phathom Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Phathom |
Filed transaction by Phathom Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Phathom Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Phathom Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Phathom Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Phathom Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Phathom Pharmaceuticals Fundamental Analysis
We analyze Phathom Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phathom Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phathom Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Phathom Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Phathom Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Phathom Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Phathom Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phathom Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Phathom Pharmaceuticals Related Equities
INZY | Inozyme Pharma | 9.56 | ||||
TERN | Terns Pharmaceuticals | 5.17 | ||||
HEPA | Hepion Pharmaceuticals | 3.28 | ||||
BPMC | Blueprint Medicines | 0.87 | ||||
LYRA | Lyra Therapeutics | 0.48 | ||||
XFOR | X4 Pharmaceuticals | 0.45 | ||||
KNSA | Kiniksa Pharmaceuticals | 0.42 | ||||
GPCR | Structure Therapeutics | 0.06 | ||||
CNSP | Cns Pharmaceuticals | 0.91 | ||||
CGEM | Cullinan Oncology | 1.18 | ||||
DAWN | Day One | 1.86 | ||||
ABOS | Acumen Pharmaceuticals | 3.56 | ||||
AMLX | Amylyx Pharmaceuticals | 7.58 | ||||
IMMX | Immix Biopharma | 13.78 |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.